No trial waiver for Sirturo in India
This article was originally published in Scrip
Executive Summary
Janssen Cilag's Sirturo (bedaquiline) for multidrug-resistant tuberculosis (MDR-TB) will need to go through phase III studies in India, after an expert panel declined the grant of a trial waiver for the product in the country.